Table 3 Infection and treatment characteristics

 ICU admission

677

22.27%

3774

18.60%

< 0.001

 Mechanical ventilation

213

7.01%

1012

4.99%

< 0.001

 Vasopressors

183

6.02%

1333

6.57%

0.252

 Dialysis

68

2.24%

389

1.92%

0.235

 Severe sepsis

537

17.66%

3549

17.49%

0.814

 Severe sepsis POA

523

17.20%

3382

16.67%

0.460

 Septic shock

386

12.70%

2274

11.21%

0.016

 Septic shock POA

360

11.84%

2049

10.10%

0.003

Monomicrobial

2184

71.84%

17,115

84.35%

< 0.001

 2 organisms

758

24.93%

2837

13.98%

< 0.001

 3 or more organisms

98

3.22%

339

1.67%

 Community-onset

2970

97.70%

19,472

95.96%

< 0.001

  Community-acquired

1465

48.19%

12,134

59.80%

  Healthcare-associated

1505

49.51%

7338

36.16%

 Hospital-onset

70

2.30%

819

4.04%

< 0.001

 CAUTI

747

24.57%

8984

44.28%

 non-CAUTI-cUTI

2293

75.43%

11,307

55.72%

< 0.001

 Blood only

12

0.39%

138

0.68%

 Urine only

917

30.16%

6321

31.15%

0.090

 Blood and urine

2111

69.44%

13,832

68.17%

 Mean (SD)

0.002

 Median [IQR]

< 0.001

Prior hospitalization within 90 days

1250

41.12%

6074

29.93%

< 0.001

Antibiotics within 90 days prior to admission

1101

36.22%

4733

23.33%

< 0.001

Antibiotics during index hospitalization prior to cUTI Index Day

225

7.40%

1594

7.86%

0.384

C3-R organism within 90 days prior to admission

356

11.71%

386

1.90%

< 0.001

FQ-R organism within 90 days prior to admission

588

19.34%

1436

7.08%

< 0.001

TMP/SMZ-R organism within 90 days prior to admission

495

16.28%

799

3.94%

< 0.001

FFM-R organism within 90 days prior to admission

1

0.03%

1

0.00%

0.244

NFT-R organism within 90 days prior to admission

307

10.10%

625

3.08%

< 0.001

TR organism within 90 days prior to admission

411

13.52%

327

1.61%

< 0.001

  Antipseudomonal penicillins with beta-lactamase inhibitor

1107

36.41%

6507

32.07%

< 0.001

  Extended spectrum cephalosporins

1651

54.31%

13,576

66.91%

< 0.001

  Antipseudomonal floroquinolones

761

25.03%

6672

32.88%

< 0.001

  Aminoglycosides

295

9.70%

1722

8.49%

0.025

  Non-PIP/TAZ penicillins with beta-lactamase inhibitors

37

1.22%

386

1.90%

0.008

  PIP/TAZ

1107

36.41%

6505

32.06%

< 0.001

  Tetracyclines

35

1.15%

238

1.17%

0.918

  Folate pathway inhibitors

39

1.28%

390

1.92%

0.014

  Polymyxins

6

0.20%

22

0.11%

0.187

  Antipseudomonal cephalosporins

646

21.25%

3913

19.28%

0.011

  Carbapenems

1317

43.32%

3287

16.20%

< 0.001

  Aztreonam

107

3.52%

784

3.86%

0.356

  Tygecycline

31

1.02%

61

0.30%

< 0.001

  C3

1245

40.95%

11,440

56.38%

< 0.001

  FQ

768

25.26%

6704

33.04%

< 0.001

  TMP/SMZ

39

1.28%

390

1.92%

0.014

  FFM

6

0.20%

42

0.21%

0.913

  NFT

38

1.25%

233

1.15%

0.625

 Non-IET

2124

69.87%

15,990

78.80%

< 0.001

 Inapproprite Empiric Treatment (IET)

597

19.64%

1101

5.43%

 Indeterminate

319

10.49%

3200

15.77%